Flow Cytometry Congress

When

2019年10月10-11日
Registration from 8am

Where

英国,伦敦
London Heathrow Marriott Hotel

Flow Cytometry Congress
-流式细胞技术学会-
日期:2019年10月10-11日
地点:英国,伦敦,London Heathrow Marriott Hotel
Choose your language
Chinese
Japanese
Korean
English

Flow Cytometry Congress

这个活动可以让您了解流式细胞仪在细胞分析和癌症诊断及治疗方面的最新技术发展和应用。重点关注流式细胞和鞘液设计的进步,新荧光团的开发以及下一代检测系统。在应用相关单元则涵括了细胞表面抗原的分析,细胞健康和死亡状态评估,细胞分选技术和肿瘤学中的药物开发。

这个学会是以癌症免疫疗法相关研究及技术为主题的一系列活动之一。报名参加这个学会,您除了可以听取这五个学会中将进行的100多场演讲之外,更可拓展您横跨各专门领域的人脉,吸收到崭新的知识。

2019年10月10日(四) – 策略及技术


主题演讲: 白血病诊断所需的半监督资料丛集和机器学习
RICHARD SCHEUERMANN, Director, Adjunct Professor, J. Craig Venter Institute
The current approach for identifying diagnostic cell populations from cytometry data in clinical labs is based on manual gating analysis, which is subjective and labor-intensive, especially with higher-dimensional complex datasets. Over the last several years, our group and others have developed a suite of computational tools and machine learning for the processing and analysis of cytometry data. To illustrate the potential use of these methods in a clinical diagnostic setting, we will present the results of a pilot project to optimize and apply a selected set of computational and machine learning methods for the automated identification of chronic lymphocytic leukemia (CLL) cells in patient samples

主题演讲: 成像流式细胞仪 - 结合强力统计分析工具的流式细胞技术和信息丰富的显微镜
ANNE WILSON, Director of the Flow Cytometry Facility, University of Lausanne (UNIL) Switzerland)
Conventional flow cytometry is a statistically powerful technology used to analyze antigen expression in populations of cells at the single cell level. It however provides little information about cell morphology, interactions between cells and localization of antigens or molecules on or within the cells, or, co-localization of molecules to cytoplasmic or nuclear structures. Imaging Flow cytometry provides all this detailed information and more at the single cell level on large numbers of cells, combining the best features of both conventional flow cytometry and microscopy. This presentation provides examples of the power and diversity of this technology.

Presentation


Morning Refreshments / Poster Presentations


Seeing more by targeting less – development of probes, prodrugs and provenance
RACHEL ERRINGTON, Chair and Principle Investigator of the Tissue MicroEnvironment Group Division of Cancer and Genetics, School of Medicine, Cardiff University
The development of both fluorescent probes is an important endeavour in cancer research useful for the drug discovery pipeline. Our simple working hypothesis is that the cellular uptake and subcellular localisation of molecules can provide important information on the status of a cell. Core to the Deep-RedAnthraQuinone (DRAQ) probe family is that the spectral-window for both excitation and emission sits in the red (>600nm) thereby making the probe suitable for studies on single cells (2D) through to thick tissue models (3D ie spheroids and organoids). Our key undertaking has been to design molecules that allow us to tune their capacity to label the nucleus versus other cellular compartments providing a greater range of signal readouts, for tracking behaviour and the emergent properties of populations

The Development of a Multicolour Antibody Panel for Mouse Bone Marrow Stromal Cells - Challenges and Breakthroughs
JANE SRIVASTAVA, Flow Cytometry Facility Manager, South Kensington Campus, Imperial College London
Why is this panel important?
• Why we chose these specific markers and fluorophores
• Some tips for the challenges of working with a large multicolour antibody panel with rare cells
• Final panel considerations and preliminary data
• Future work


Lunch


Implementation of Multi-Parameter Flow Cytometry Assays in Clinical Trials
VILMA DECMAN, Associate Director Flow Cytometry, Bristol-Myers Squibb
Flow cytometry is a powerful technique in the research, drug development and clinic as it allows for the examination of multiple targets on various cell subsets from a limited sample size. Its ability to identify and enumerate different cellular markers and track them across time and treatment aids in understanding of disease pathology, toxicological assessment of new drugs and their efficacy. This talk will concentrate on implementation of multi-parameter flow cytometry in clinical trials including:
• Understanding of biomarker needs in development of high-dimensional flow cytometry assays
• Design and optimization of panels; potential pitfalls
• Validation of assay/standardization
• Sample logistics
• New technology platforms

An in vivo approach to the early photoacoustic detection of infectious diseases and blood conditions
VLADIMIR ZHAROV, Professor, Director, University of Arkansas for Medical Sciences, Arkansas Nanomedicine Center

60 MINUTE INTERACTIVE WORKSHOP


Afternoon Refreshments / Poster Presentations


Standardizing technical practise across labs - developing an automated shared resource library
CHRIS GROVES, Senior Manager, MedImmune

Data-driven cytometry
RYAN BRINKMAN, Professor, Medical Genetics, University of British Columbia Distinguished Scientist, BC Cancer CEO, Cytapex Bioinformatics Inc.
Manual analysis of flow cytometry data is subjective and time consuming. Automated algorithms have reached a level of maturity that enables them to match and, in many cases, exceed the results produced by human experts. The current state-of-the-art will be reviewed though example applications of these algorithms in automating the entire data analysis pipeline. Examples will include automated quality checking at the event and sample level, rapid, robust and reproducible automated gating and biomarker discovery algorithms. The utility of these algorithms will be shown through their application on patient data for basic research, clinical trials and drug discovery.


Networking Drinks Reception


2019年10月11日(五) - 细胞级分析及其在肿瘤治疗的应用

主题演讲: 从干细胞到血液细胞:分化途径的流式细胞技术
FRANK PREIJERS, Radboud University Medical Center, Nijmegen, The Netherlands
Flow cytometry (FCM) is increasingly used in clinical laboratories for diagnosis of various hematological disease. The rapid and sensitive multi-parameter detection renders FCM to a powerful tool to distinguish malignant cells from normal. Pattern recognition of fluorescence expression levels of conjugates and combinations in the various cells activation stages is hereby essential. However, before aberrancies can be established, the normal hematopoiesis must be studied. Bone marrow contains all differentiation stages of hematopoiesis. The maturation can be monitored by changes in immunophenotype, identified by a unique combination of MoAbs.
Each antigen is expressed by an appropriate expression pattern during the maturation. Frequently, neoplastic cells possess aberrant immunophenotypes. More or less antigens and antigen expression on different levels can be found in these leukemic cells. This implies that knowledge of the normal cell maturation patterns facilitates recognition of malignant cells. We studied the maturation pathways from stem cells to myeloid, monocytic and erytroid lineage cells using a 10-color NaviosTM (Beckman Coulter) and KaluzaTM analysis software.

Identifying new forms of cell death - using flow cytometry to explore cell fate
GARY WARNES Flow Cytometry Core Facility Manager, Blizard Institute, Barts and London School of Medicine & Dentistry, Queen Mary London University
• RIP3 and Caspase-3 intracellular labelling with a fixable live/dead probe allows the flow cytometric detection of necroptosis (RIP3high+ve/Caspase-3-ve) , apoptosis (RIP3-ve/Caspase-3+ve) and RIP1-dependent apoptosis (RIP3+ve/Caspase-3+ve)
• Further labelling with LC3B allows the detection of autophagic cells
• Additional labelling with H2AX and PARP allows further identification of DNA damage, hyper-action of PARP and parthanatos
• Incidences of RCD were modulated by the use of zVAD and Necrostain-1
• Autophagy was shown to protect cells by reducing DNA damage
• Use of MitoTracker and violet live cell caspase probe allows the identification of necroptosis and apoptosis in unfixed cells
• Additional use of fixable probes for mitochondrial function and Reactive Oxygen Species (ROS) extends the number of identifiable cell death populations to 500


Morning Refreshments / Poster Presentations


Starting up clinical trials with TCR-modified T cells in solid cancers
DAVID BAKER Senior Research Scientist, AstraZeneca
• The high-throughput flow cytometry capability at AZ and examples of how this has been used.
• Applications of high-throughput flow cytometry in immuno-oncology projects (assays such as T-cell proliferation, activation, tumour killing assays).

Applications of flow cytometry in early phase oncology trials
STEPHANIE TRAUB,Cancer Research UK
The presentation will outline the use of flow cytometry in early phase clinical development with relevant examples of commonly encountered challenges and suggested solutions.


Lunch


Developing a GUCY2C-Targeted Adoptive T Cell Therapy
FRIDTJOF LUND-JOHANSEN, Head of flow cytometry core facility, Oslo University Hospital, Norway
Proteomics is still a small discipline where the research front is driven by a few laboratories with unrestricted access to mass spectrometry (MS). With MAP, we put the power of proteomics into the hands of flow cytometry (FCM) users. Bead-based arrays with a multiplexing capacity up to 5000 provide the convenience and throughput needed to take proteomics to the next level. The challenge lies in changing the mindset that keeps the western blot on top of the list of the most popular antibody applications. The FCM version is called Western-MAP and yields results for thousands of antibodies in parallel. In Native-MAP, proteins are separated by size exclusion chromatography for large-scale analysis of protein complexes. Thus, MAP turns the flow cytometer into a high throughput proteomics machine.

Analysing t cells for neo-antigen specificity
PIA KVISTBORG (Reserved), Junior Group Leader, NKI Amsterdam


Chair’s Closing Remarks / Conference Close


 

* 活动内容有可能不事先告知作更动及调整。

议程

由于这个学会针对的是参与研究流式细胞技术 - 这个提供了细胞特性之可定量化数据所需的重要方法之技术领域人士,所以将吸引350以上该领域的专家。

Download the Agenda (PDF)

演讲者

赞助商

所有赞助商名单

地点

London Heathrow Marriott Hotel

London Heathrow Marriott900

Bath Road, Harlington, Hayes, Middlesex, UB3 5AN

海报发表

海报发表除了在休息时间之外,更与分组会议单元同时进行。制药公司和研究机关的研究人员制所作的海报,会在通过学会审核之后,于会场内指定区域展示。

我们还会向所有与会者发放海报电子书,如果您愿意,可以在会议结束后以PDF格式分享您的海报(可自由选择)。

无论是寻找资金,就业机会还是只是想与志同道合,专心致力的研究团队分享您的工作成果,会场内的海报都是让您吸引众人注目的宝贵机会。

为了在论坛上展示海报,您需要报名登记参加学会。海报展示空间有限,将依报名顺序加以审核,恳请提早报名以免向隅。

我们向行业代表收取100英镑的管理费,用于提供海报展示区和展板,指南等共同费用。代表学术机构而非营利组织的人则免收这笔费用。

海报发表的申请方法

请填写专用表格 (下列链接可下载) ,在2019年9月20日前提交。但因空间有限,敬请早日申请以免向隅,如有任何问题请洽询联络处。

学会的赞助商

募集赞助商

成为这个学会的赞助商或参展商,您可在融洽的气氛中,一面和专家们交流彼此的意见,同时也有机会和各种组织代表进行官方或非官方会谈,以建立彼此的合作关系。

此外我们更准备了各种赞助商配套方案,您可考量自身的预算及业务需求,选择能让您获得最大投资收益的方案。

如果您有除此之外,成为赞助商来开展您宣传活动的其他建议,也欢迎您随时与我们连络,我们将配合您的需求提供各种提案。

可事前预约的二十分钟一对一个别会谈

在主要会议议程的分组会议期间将举行一系列事先预约的二十分钟个别会谈,选择您想要会见的代表。在会议期间Global Engage的团队将随时待命,确保您的所有会议按时举行。

主要会议前后的研讨会

在主要会议前后,将举办为了对特定主题有兴趣的与会者所办的全天或半天研讨会。Global Engage将协助您在研讨会上进行宣传活动,并确保够多人出席。

学会开幕前的行销和品牌宣传

您也可利用Global Engage的资料库来进行行销,更可揭示海报,成为休息和午餐会、招待会、海报单元的赞助商来提升您的品牌知名度。此外我们也另外提供可在发给与会者的挂绳,和学会资料袋上印刷标志以提升品牌知名度的选项。

参展

会期中,您可在会场内所设的专用区向所有的与会者发表您的技术及产品。展会区同时也是休息及午餐会,第一天傍晚举行的招待会的会场。

演讲

演讲的形态

  • 30分钟的演讲
  • 以主持人或小组成员身分参加30分钟专题研讨会
  • 在学会的议程中召开1小时的研讨会
募集赞助商

详细内容请洽询GII联络处。

包括签证等各种海关所需文件,以及展示用品的通关手续皆由展商企业各自负责。

展示相关的安排(企业介绍、公司商标、提供与会者目录中的展商资讯登录、展示空间的装潢、用品订购、展示用品的摆设搬运、展示空间的文件申请、保险等)请直接与主办方连系。

旅游相关疑问(住宿、机票)、当地翻译人员、飞行与意外保险等问题,将有另外的专门业者分别提供服务。

Flow Cytometry Congress的赞助商相关详情请洽询联络处。

关于与会者、配套方案、新募集情报等详细资讯,请洽询联络处。我们将竭诚为您提供关于您评估这场活动所需的所有资讯。

媒体合作伙伴

  • 247 Updates
  • Bentham Science
  • Biocompare
  • Biotechgate
  • EIN Presswire
  • Global Information
  • Pharma Journalist
  • PharmaVOICE
  • SciDoc Publishers
  • Pharmaceutical Tech
 
免费电子邮件通知服务